RP-HPLC method for the quantitative determination of fexofenadine hydrochloride in coated tablets and human serum

Medicinal Chemistry Research

Volumn 20, Issue 1, 2011, Pages 55-61

  Arayne, M Saeed ^a   Sultana, Najma ^a   Shehnaz, Hina ^a   Haider, Amir ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

Fexofenadine; Five different stationary phases; High performance liquid chromatography; Isocratic; Robustness; Urticaria

Indexed keywords

FEXET; FEXOFAST; FEXOFENADINE; METHANOL; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; BLOOD SAMPLING; DRUG DETERMINATION; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; PH; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TABLET FORMULATION;

EID: 79952707288     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00044-009-9285-6     Document Type: Article

References (26)

1. Arayne MS, Sultana N, Siddiqui FA (2005) Determination and quantification of cetirizine HCl in dosage formulations by RPHPLC. Pak J Pharm Sci 18:7-11
2. Arayne MS, Sultana N, Nawaz M (2008) Simultaneous quantification of cefpirome and cetirizine or levocetirizine in pharmaceutical formulations and human plasma by RP-HPLC. J Anal Chem 63:881-887
3. Barnes CL, McKenzie CA, Webster KD, Poinsett-Holmes K (1993) Cetirizine: a new, non-sedating antihistamine. Ann Pharmacother 27:464-470
4. British Pharmacoepia (2000) Her Majesty Stationary Office, pp 342-343
5. Caballero E, Ocaña I, Azanza JR, Sádaba B (1999) Fexofenadine: a antihistaminic review of its practical characteristics. Rev Med Univ Navarra 43:93-97
6. CDER: Center for Drug Evaluation and Research (1994) Reviewer guidance for validation of chromatographic methods. Disponívelem: http://www.fda.gov/cder/guidance/cmc3.pdf
7. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum M, Fromm MF (2002) MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 53:526-534 (Pubitemid 34527155)
8. Fu I, Woolf EJ, Matuszewski BK (2004) Determination of fexofenadine in human plasma using 96-well solid phase extraction and HPLC with tandem mass spectrometric detection. J Pharm Biomed Anal 35:837-846 (Pubitemid 38757674)
9. 1 receptor antagonists in dosage forms. J Pharm Biomed Anal 30:859-867
10. Gergov M, Robson JN, Ojanperä I, Heinonen OP, Vuori E (2001) Simultaneous screening and quantification of 18 antihistamine drugs in blood by liquid chromatography ionspray tandem mass spectrometry. Forensic Sci Int 121:108-115 (Pubitemid 32758820)
11. Gowekar NM, Pande VV, Kasture AV, Tekade AR, Chandorkar JG (2007) Spectrophotometric estimation of ambroxol and cetirizine hydrochloride from tablet dosage form. Pak J Pharm Sci 20:250-251
12. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD (2001) The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 69:114-121 (Pubitemid 32225411)
13. ICH guidelines Topic Q2 (R1) Validation of analytical procedures: methodology. www.emea.europa.eu/htms/human/ich/ichquality.htm.
14. 1- antihistamine-induced urticaria. J Dermatol 36:224-227
15. Karakuş S, Küçükgüzel I, Küçükgüzel SG (2008) Development and validation of a rapid RP-HPLC method for the determination of cetirizine or fexofenadine with pseudoephedrine in binary pharmaceutical dosage forms. J Pharm Biomed Anal 46:295-302 [Epub 2007 October 22]
16. Markham A, Wagstaff AJ (1998) Fexofenadine. Drugs 55:269-274 discussion 275-276
17. Mattila MJ, Paakkari I (1999) Variations among non-sedating antihistamines: are there real differences? Eur J Clin Pharmacol 55:85-93
18. Milne RW, Larsen LA, Ãrgensen KLJ, Bastlund J, Stretch GR, Evans AM (2000) Hepatic disposition of fexofenadine: influence of the transport inhibitors erythromycin and dibromosulphothalein. Pharm Res 17:1511-1515 (Pubitemid 32217560)
19. Naidong W, Shou WZ, Addison T, Maleki S, Jiang X (2002) Liquid chromatography/tandem mass spectrometric bioanalysis using normal-phase columns with aqueous/organic mobile phases - a novel approach of eliminating evaporation and reconstitution steps in 96-well SPE. Rapid Commun Mass Spectrom 16:1965-1975
20. Pathak SM, Kumar AR, Musmade P, Udupa N (2008) A simple and rapid high performance liquid chromatographic method with fluorescence detection for the estimation of fexofenadine in rat plasma - application to preclinical pharmacokinetics. Talanta 76:338-346 [Epub 2008 March 13]
21. Pratt C, Brown AM, Rampe D, Mason J, Russell T, Reynolds R, Ahlbrandt R (1999) Cardiovascular safety of fexofenadine HCl. Clin Exp Allergy 29:212-216 (Pubitemid 29333360)
22. Radhakrishna T, Om Reddy G (2002) Simultaneous determination of fexofenadine and its related compounds by HPLC. J Pharm Biomed Anal 29:681-690 (Pubitemid 34687024)
23. Russell T, Stoltz M, Weir S (1998) Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther 64:612-621 (Pubitemid 29011381)
24. Simpson K, Jarvis B (2000) Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 59:301-321 (Pubitemid 30168518)
25. Sultana N, Arayne MS, Shamshad H (2009) In vitro studies of the interaction between cetirizine and H2 receptor antagonists using spectrophotometry and reversed-phase high-performance liquid chromatography. Med Chem Res. doi:10.1007/s00044-009-9204-x
26. Uno T, Yasui-Furukori N, Takahata T, Sugawara K, Tateishi T (2004) Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection. J Pharm Biomed Anal 35:937-942 (Pubitemid 38757685)